Rowland J Bright-Thomas
Overview
Explore the profile of Rowland J Bright-Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tewkesbury D, Scott J, Bright-Thomas R, Liong S, Naish J, Rudralingam V, et al.
PLoS One
. 2025 Mar;
20(3):e0318085.
PMID: 40036270
Background: Current diagnostic tools are limited in their ability to diagnose cystic fibrosis liver disease (CFLD) as disease is often focal in nature. Magnetic resonance extracellular volume quantification (MRI ECV)...
2.
Sapru K, Wilkinson J, Webb A, Akhtar M, Bright-Thomas R
Pediatr Pulmonol
. 2025 Jan;
60(1):e27472.
PMID: 39812352
Background: The vast majority of men with CF (mwCF) are infertile. Improvements in assisted reproductive technology (ART) have made it possible for these patients to become biological fathers. Methods: Data...
3.
Woywodt A, Dhanda R, van Dellen D, So B, Bright-Thomas R
Front Transplant
. 2024 Jul;
1:992985.
PMID: 38994374
Cystic fibrosis (CF) is a multisystem disorder and represents the most common inherited condition leading to death in Western countries. Previous reports of chronic kidney disease (CKD) in CF focus...
4.
Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis
Tewkesbury D, Scott J, Barry P, Bright-Thomas R, Piper Hanley K, Athwal V, et al.
J Cyst Fibros
. 2023 Sep;
23(2):349-353.
PMID: 37735009
Background: There are limited studies to date on the effects of elexacaftor/tezacaftor/ivacaftor (E/T/I) on markers of liver fibrosis in adults with cystic fibrosis (CF). This study aims to analyse changes...
5.
Tewkesbury D, Athwal V, Bright-Thomas R, Jones A, Barry P
J Cyst Fibros
. 2023 Jan;
22(2):256-262.
PMID: 36669962
Background: Elexacaftor/tezacaftor/ivacaftor (E/T/I) therapy has resulted in substantial improvements in health status for many with cystic fibrosis. Monitoring of liver tests is recommended due to observed rises in transaminases in...
6.
van Rhijn N, Coleman J, Collier L, Moore C, Richardson M, Bright-Thomas R, et al.
Front Cell Infect Microbiol
. 2021 Dec;
11:759944.
PMID: 34900752
Background: Cystic fibrosis is an inherited disease that predisposes to progressive lung damage. Cystic fibrosis patients are particularly prone to developing pulmonary infections. Fungal species are commonly isolated in lower...
7.
Tewkesbury D, Dhanda R, Looi E, Bright-Thomas R
Br J Hosp Med (Lond)
. 2021 Nov;
82(10):1-3.
PMID: 34726944
No abstract available.
8.
Dennis J, Jones A, Davies E, Welfare W, Barry P, Collier L, et al.
J Cyst Fibros
. 2020 Jun;
19(5):808-814.
PMID: 32565192
Introduction: An outbreak of Influenza B occurred at a large United Kingdom (UK) regional adult cystic fibrosis (CF) centre in May 2016. This was late in the UK 2015-2016 influenza...
9.
Pearmain L, Gupta R, Bright-Thomas R
Clin Med (Lond)
. 2020 Jan;
20(1):101-104.
PMID: 31941741
We present the case of an 83-year-old woman, with known asthma, admitted with increasing dyspnoea, wheeze and a productive cough. In addition to maintenance inhaled therapy, the patient was also...
10.
Kenna D, Coward A, Perry C, Pike R, Schaefer U, Turton J, et al.
J Med Microbiol
. 2019 Jun;
68(7):1081-1095.
PMID: 31210630
Purpose: We examined evidence for transmission of Pandorea apista among cystic fibrosis (CF) patients attending paediatric and adult services in one city who had previously been found to harbour related...